s6y

Larimar Therapeutics, Inc.

Ticker
LRMR
CIK
1374690
Industry
Pharmaceutical Preparations
Formerly
ZAFGEN, INC., ZAFGEN INC

Financials 51

  1. 10-Q Quarterly Report for period ending Sep 30, 2026
  2. 10-Q Quarterly Report for period ending Jun 30, 2026
  3. 10-Q Quarterly Report for period ending Mar 31, 2026
  4. 10-K Annual Report for period ending Dec 31, 2025
  5. 10-Q Quarterly Report for period ending Sep 30, 2025
  6. 10-Q Quarterly Report for period ending Jun 30, 2025
  7. 10-Q Quarterly Report for period ending Mar 31, 2025
  8. 10-K Annual Report for period ending Dec 31, 2024
  9. 10-Q Quarterly Report for period ending Sep 30, 2024
  10. 10-Q Quarterly Report for period ending Jun 30, 2024

All 51 financials filings

News 154

  1. 8-K Current report filing
  2. 8-K Current report filing
  3. 8-K Current report filing
  4. 8-K Current report filing
  5. 8-K Current report filing
  6. 8-K Current report filing
  7. 8-K Current report filing
  8. 8-K Current report filing
  9. 8-K Current report filing
  10. 8-K Current report filing

All 154 news filings

Ownership 366

  1. 4 Statement of changes in beneficial ownership of securities
  2. 4 Statement of changes in beneficial ownership of securities
  3. 4 Statement of changes in beneficial ownership of securities
  4. 4 Statement of changes in beneficial ownership of securities
  5. 4 Statement of changes in beneficial ownership of securities
  6. 4 Statement of changes in beneficial ownership of securities
  7. 4 Statement of changes in beneficial ownership of securities
  8. 4 Statement of changes in beneficial ownership of securities
  9. 4 Statement of changes in beneficial ownership of securities
  10. 4 Statement of changes in beneficial ownership of securities

All 366 ownership filings

Prospectus 49

  1. S-8 Initial registration statement for securities to be offered to employees pursuant to employee benefit plans
  2. S-8 Initial registration statement for securities to be offered to employees pursuant to employee benefit plans
  3. 424B5 Prospectus filed pursuant to Rule 424(b)(5)
  4. 424B5 Prospectus filed pursuant to Rule 424(b)(5)
  5. 424B5 Prospectus filed pursuant to Rule 424(b)(5)
  6. 424B5 Prospectus filed pursuant to Rule 424(b)(5)
  7. S-8 Initial registration statement for securities to be offered to employees pursuant to employee benefit plans
  8. S-3 Registration statement for specified transactions by certain issuers
  9. S-8 Initial registration statement for securities to be offered to employees pursuant to employee benefit plans
  10. S-8 Initial registration statement for securities to be offered to employees pursuant to employee benefit plans

All 49 prospectus filings

Proxies 25

  1. DEF 14A Definitive proxy statements
  2. PRE 14A Preliminary proxy statement not related to a contested matter or merger/acquisition
  3. DEF 14A Definitive proxy statements
  4. DEF 14A Definitive proxy statements
  5. PRE 14A Preliminary proxy statement not related to a contested matter or merger/acquisition
  6. DEF 14A Definitive proxy statements
  7. DEF 14A Definitive proxy statements
  8. DEF 14A Definitive proxy statements
  9. DEFA14A Definitive additional proxy soliciting materials including Rule 14(a)(12) material. Note: Submission type DEFA14A can be filed as part of Form 8-K. For filers subject to 8-K filing requirements, we recommend the use of the 8-K combined form type as the easiest method for fulfilling your filing requirement for both forms.
  10. DEF 14A Definitive proxy statements

All 25 proxies filings

Other 65

  1. SCHEDULE 13G
  2. SCHEDULE 13G/A
  3. SCHEDULE 13G/A
  4. ARS Annual report to security holders
  5. SCHEDULE 13D/A
  6. SCHEDULE 13G/A
  7. SCHEDULE 13G/A
  8. SCHEDULE 13G/A
  9. SCHEDULE 13G
  10. SCHEDULE 13G/A

All 65 other filings